The care of patients living with psoriasis in Latin America represents many unique challenges due to lack of knowledge on the burden of psoriasis in this region and limited access to care. IPC’s working group assembles regional experts to highlight these issues on an international stage, bringing influence and awareness to dermatologists throughout the region.
Determine priorities and issues specific to Latin America, including access to care, education, and comorbidities.
Contribute to the Global Psoriasis Atlas.
The International Psoriasis Council (IPC) is continuing efforts to focus and enrich the knowledge and advancement of care of patients with psoriasis in Latin America. Since 2011, IPC has fostered psoriasis leadership in the region, conducted educational programs, and examined issues specific to Latin America, such as limited healthcare resources and limited access to biologics. The working group conducts educational symposia at major congresses in Latin America and publishes manuscripts on important clinical issues in the region.
Claudia de la Cruz, MD Clinica Dermacross Santiago, Chile IPC Board Member
Claudia de la Cruz received her medical degree from Universidad de Chile, Sede Oriente, Hospital de Salvador, Hospital, U. Chile, Chile. She received her dermatology training at Universidad de Chile, Hospital Jose Joaquinaguirre . She maintains academic affiliations with Universidad Católica de Chile as an Assistant Professor in Dermatology. She is also very active in the Chilean Society of Dermatology and is the coordinator of the psoriasis group and is a member of the National Ministry of Health Committee for Psoriasis Disease. Dr. de la Cruz has also published several papers on psoriasis and has presented at both national and international congresses on psoriasis and related issues. She is fluent in Spanish and English.
Last Updated: May 07, 2019
Ricardo Romiti, MD, PhD University of São Paulo Brazil São Paulo, Brazil IPC Board Member
Ricardo Romiti, MD, PhD, is responsible for the Psoriasis Unit at the Department of Dermatology of the University of São Paulo, Brazil, and works as clinical Professor of Dermatology also at the University of São Paulo. Having gained his medical degree from the Faculty of Medicine of the University of São Paulo, where he also completed his residency in the Department of Dermatology, Professor Romiti undertook a Fellowship at the “Ludwig-Maximilians-Universität”, Munich, Germany. Professor Romiti has authored or co-authored numerous papers published in national and international dermatology journals and is the editor of five books with a focus on psoriasis. In addition, Professor Romiti is currently board director of the International Psoriasis Council (IPC) and responsible for the Psoriasis Department at the Brazilian Society of Dermatology.
Last Updated: Jan 25, 2018
de la Cruz C, de Carvalho AV, Dorantes GL, Londoño Garcia AM, Gonzalez C, Maskin M, Podoswa N, Redfern JS, Valenzuela F, van der Walt J, Romiti R. J Dermatol. 2017 Jan;44(1):3-12. doi: 10.1111/1346-8138.13512. 27461455, Epub 2016 Jul 27.
Abstract
Latin American countries view biosimilar agents as an effective approach to curtail health-care expenditures while maintaining the safety and efficacy profile of their branded innovator comparators. To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Council convened dermatology experts from Argentina, Brazil, Chile, Colombia and Mexico in October 2015 to review the definition, approval, marketing and future of biosimilars in each country and develop a consensus statement. The regulatory framework for marketing approval of biosimilars in Latin America is currently a mosaic of disparate, country-specific, regulatory review processes, rules and standards, with considerable heterogeneity in clarity and specificity. Regulations in Argentina, Brazil, Chile and Mexico have undergone multiple refinements whereas Colombia is finalizing draft guidelines. Verification of the similarity in quality, safety and efficacy of biosimilars to the innovator biologic remains a key challenge for policy makers and regulatory authorities. Other key regulatory challenges include: naming of agents and traceability, pharmacovigilance, extrapolation of indications, and interchangeability and substitution. An urgent need exists for more Latin American countries to establish national psoriasis registries and to integrate their common components into a multinational psoriasis network, thereby enhancing their interpretative power and impact. A Latin American psoriasis network similar to PSONET in Europe would assist health-care providers, pharmaceutical companies, regulators and patients to fully comprehend specific products being prescribed and dispensed and to identify potential regional trends or differences in safety or outcomes.
Link to full publication
RADLA 2018 | Qué hay de nuevo en psoriasis? Un actualización por el International Psoriasis Council
On-Demand Webcast